CytoDyn Inc., a late stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications and Samsung BioLogics met at the Samsung BioLogics Songdo headquarters for an official signing ceremony of the manufacturing agreement with Samsung BioLogics that was previously announced on April 2, 2019.
May 30, 2019
· 8 min read
